133 related articles for article (PubMed ID: 2498095)
21. [Bactericidal activity of imipenem].
Thabaut A; Meyran M
Presse Med; 1990 Apr; 19(13):592-7. PubMed ID: 2139938
[TBL] [Abstract][Full Text] [Related]
22. Pseudoresistance of Pseudomonas aeruginosa resulting from degradation of imipenem in an automated susceptibility testing system with predried panels.
White RL; Kays MB; Friedrich LV; Brown EW; Koonce JR
J Clin Microbiol; 1991 Feb; 29(2):398-400. PubMed ID: 1822083
[TBL] [Abstract][Full Text] [Related]
23. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
Kresken M; Körber-Irrgang B; Läuffer J; Decker-Burgard S; Davies T
Int J Antimicrob Agents; 2011 Jul; 38(1):70-5. PubMed ID: 21514795
[TBL] [Abstract][Full Text] [Related]
24. Postantibiotic effect of carbapenems against Pseudomonas aeruginosa.
Hikida M; Yamazaki Y; Yoshida M; Kawashima K; Nishiki K; Mitsuhashi S
J Antibiot (Tokyo); 1995 Aug; 48(8):891-2. PubMed ID: 7592037
[No Abstract] [Full Text] [Related]
25. Resistance of artificial biofilms of Pseudomonas aeruginosa to imipenem and tobramycin.
Coquet L; Junter GA; Jouenne T
J Antimicrob Chemother; 1998 Dec; 42(6):755-60. PubMed ID: 10052899
[TBL] [Abstract][Full Text] [Related]
26. Increase of imipenem resistance among Pseudomonas aeruginosa isolates from a Polish paediatric hospital (1993-2002).
Patzer JA; Dzierzanowska D
Int J Antimicrob Agents; 2007 Feb; 29(2):153-8. PubMed ID: 17157481
[TBL] [Abstract][Full Text] [Related]
27. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
Lister PD; Wolter DJ
Clin Infect Dis; 2005 Feb; 40 Suppl 2():S105-14. PubMed ID: 15712098
[TBL] [Abstract][Full Text] [Related]
28. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
Turner PJ
Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
[TBL] [Abstract][Full Text] [Related]
29. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
[TBL] [Abstract][Full Text] [Related]
30. [In vitro study of the bacteriostatic and bactericidal activity of meropenem against strains of Pseudomonas aeruginosa multiresistant to antibiotics].
Delisle F; Lesage D; Barakett V; Richard G; Petit JC
Pathol Biol (Paris); 1996 May; 44(5):337-40. PubMed ID: 8758471
[TBL] [Abstract][Full Text] [Related]
31. Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems.
Mizunaga S; Kamiyama T; Fukuda Y; Takahata M; Mitsuyama J
J Antimicrob Chemother; 2005 Jul; 56(1):91-6. PubMed ID: 15890721
[TBL] [Abstract][Full Text] [Related]
32. Postantibiotic effects of three carbapenems on Pseudomonas aeruginosa in the presence of lysine.
Boswell FJ; Andrews JM; Gill MJ; Wise R
J Antimicrob Chemother; 1995 Jan; 35(1):232-3. PubMed ID: 7768777
[No Abstract] [Full Text] [Related]
33. Detection of outer membrane porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates.
Naenna P; Noisumdaeng P; Pongpech P; Tribuddharat C
Southeast Asian J Trop Med Public Health; 2010 May; 41(3):614-24. PubMed ID: 20578550
[TBL] [Abstract][Full Text] [Related]
34. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.
Aubert G; Pozzetto B; Dorche G
J Antimicrob Chemother; 1992 Mar; 29(3):307-12. PubMed ID: 1317371
[TBL] [Abstract][Full Text] [Related]
35. [Rapid bactericidal activities of carbapenems against Pseudomonas aeruginosa in simulating human plasma concentrations].
Ishii C; Kakuta M; Abe T; Fukuoka T; Inoue M
Jpn J Antibiot; 2002 Apr; 55(2):187-95. PubMed ID: 12071096
[TBL] [Abstract][Full Text] [Related]
36. Outer membrane proteins profiles of Pseudomonas aeruginosa after the post-antibiotic effect of imipenem.
Hostacká A; Karelová E
Microbios; 1997; 90(362):45-50. PubMed ID: 9301070
[TBL] [Abstract][Full Text] [Related]
37. Resistance to imipenem in Pseudomonas aeruginosa.
King A; Shannon K; Phillips I
J Antimicrob Chemother; 1995 Dec; 36(6):1037-41. PubMed ID: 8821603
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of fosfomycin-gentamicin, fosfomycin-ceftazidime, fosfomycin-imipenem and ceftazidime-gentamicin combinations against ceftazidime-resistant Pseudomonas aeruginosa.
Pruekprasert P; Tunyapanit W
Southeast Asian J Trop Med Public Health; 2005 Sep; 36(5):1239-42. PubMed ID: 16438151
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
Yadav R; Bulitta JB; Wang J; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993331
[TBL] [Abstract][Full Text] [Related]
40. Ultrastructural alterations of bacteria during the postantibiotic effect.
Gottfredsson M; Erlendsdóttir H; Kolka R; Gudmundsson A; Gudmundsson S
Chemotherapy; 1993; 39(3):153-62. PubMed ID: 8508685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
